Early Trigger for Sterility, Female

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Fertility center of Las Vegas, Las Vegas, NV
Sterility, Female+1 More
Ovulatory trigger timing - Procedure
Eligibility
18 - 65
Female
What conditions do you have?
Select

Study Summary

This randomized trial will compare the efficacy of two different times of administration of medications for final oocyte maturation, commonly called a "trigger", in cycles of controlled ovarian stimulation (COS) for cycles in which all embryos will be cryopreserved ("freeze-all cycles").

Eligible Conditions

  • Sterility, Female

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Sterility, Female

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Within 7 days of oocyte retrieval

Day 7
Delayed blastocyst formation
Good-quality blastocysts

Trial Safety

Safety Progress

1 of 3

Other trials for Sterility, Female

Trial Design

2 Treatment Groups

Early Trigger
1 of 2
Delayed trigger
1 of 2
Experimental Treatment

150 Total Participants · 2 Treatment Groups

Primary Treatment: Early Trigger · No Placebo Group · N/A

Early Trigger
Procedure
Experimental Group · 1 Intervention: Ovulatory trigger timing · Intervention Types: Procedure
Delayed trigger
Procedure
Experimental Group · 1 Intervention: Ovulatory trigger timing · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: within 7 days of oocyte retrieval

Trial Background

Bruce Shapiro M.D., Medical Director
Principal Investigator
Fertility Center of Las Vegas
Closest Location: Fertility center of Las Vegas · Las Vegas, NV
Photo of las vegas  1Photo of las vegas  2Photo of las vegas  3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Sterility, Female
0 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.